Jan 24, 2025 · Amycretin is a unimolecular long-acting GLP-1 and amylin receptor agonist under development by Novo Nordisk, to provide an efficacious and convenient treatment for adults with overweight or obesity and as a treatment for adults with type 2 diabetes.

Feb 3, 2025 · Novo Nordisk plans further clinical development of amycretin for obesity and overweight treatment. ... Amycretin (Novo Norisk) led to a reduction in body weight across the 20-week, 28-week, and 36-week periods, with weight loss of up to 22%, according to results from a randomized control trial. 1.

Sep 12, 2024 · Early findings from a phase 1 clinical trial first announced by the Danish company Novo Nordisk in March 2024, show that amycretin — an experimental drug they have developed to treat obesity...

3 days ago · Novo Nordisk has been boosted by data for an oral obesity therapy, amycretin, that was more effective than injectable Wegovy at reducing weight in a clinical trial.

Jan 28, 2025 · With amycretin, Novo Nordisk expects to improve on the efficacy of its blockbuster drug semaglutide, sold under the brand names Ozempic and Wegovy. Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, a class of drugs that have rapidly gained in popularity in recent years due to their significant weight loss effects. In comparison ...

Jan 24, 2025 · Novo Nordisk reported today that amycretin, an investigational glucagon-like peptide-1 (GLP-1) and amylin receptor agonist, led to significant weight reductions in individuals with overweight or obesity in a phase 1b/2a clinical trial. 1

Jan 27, 2025 · Novo Nordisk has reported topline outcomes from a Phase Ib/IIa trial of amycretin designed for treating obese or overweight individuals. The trial assessed the safety, pharmacokinetics, efficacy, proof-of-concept and tolerability of the unimolecular glucagon-like peptide 1 (GLP-1) and amylin receptor agonist.

Sep 23, 2024 · In a phase 1 trial, Novo Nordisk's experimental obesity drug amycretin led to up to 13% weight loss in just three months. Amycretin targets GLP-1 receptors and a second hormone called amylin. Amylin appears to act in the brain, rather than in the gut.

Sep 11, 2024 · Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more rapid weight loss than its popular obesity injection Wegovy.

Feb 5, 2025 · Novo Nordisk's sales increased by 25% in Danish kroner and by 26% at constant exchange rates to DKK 290.4 billion in 2024. Bagsværd, ... Lastly, a phase 1b/2a with injectable amycretin in people with overweight or obesity was successfully completed. In December 2024, Novo Nordisk announced that the acquisition of Catalent by Novo Holdings and ...